TFG Advisers LLC Buys 159 Shares of Stryker Co. (NYSE:SYK)

TFG Advisers LLC raised its stake in Stryker Co. (NYSE:SYK) by 1.2% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 13,683 shares of the medical technology company’s stock after acquiring an additional 159 shares during the quarter. Stryker makes up 1.8% of TFG Advisers LLC’s portfolio, making the stock its 8th biggest holding. TFG Advisers LLC’s holdings in Stryker were worth $4,943,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Commerzbank Aktiengesellschaft FI grew its stake in Stryker by 141.4% in the 3rd quarter. Commerzbank Aktiengesellschaft FI now owns 3,577 shares of the medical technology company’s stock worth $1,292,000 after acquiring an additional 2,095 shares during the period. Weaver Capital Management LLC boosted its holdings in shares of Stryker by 48.0% during the third quarter. Weaver Capital Management LLC now owns 3,471 shares of the medical technology company’s stock worth $1,254,000 after purchasing an additional 1,125 shares during the last quarter. Liberty Capital Management Inc. grew its position in shares of Stryker by 2.7% in the third quarter. Liberty Capital Management Inc. now owns 11,543 shares of the medical technology company’s stock valued at $4,170,000 after purchasing an additional 301 shares during the period. GAM Holding AG increased its stake in Stryker by 7.1% in the third quarter. GAM Holding AG now owns 10,787 shares of the medical technology company’s stock valued at $3,897,000 after purchasing an additional 714 shares during the last quarter. Finally, Private Advisor Group LLC lifted its position in Stryker by 3.4% during the third quarter. Private Advisor Group LLC now owns 15,967 shares of the medical technology company’s stock worth $5,768,000 after buying an additional 526 shares during the period. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Stock Down 1.1 %

Shares of SYK traded down $3.96 during mid-day trading on Wednesday, reaching $362.06. 49,815 shares of the stock traded hands, compared to its average volume of 1,244,238. The firm has a market cap of $137.93 billion, a price-to-earnings ratio of 41.80, a P/E/G ratio of 2.85 and a beta of 0.91. The stock has a fifty day simple moving average of $357.37 and a 200 day simple moving average of $343.45. The company has a quick ratio of 0.95, a current ratio of 1.68 and a debt-to-equity ratio of 0.51. Stryker Co. has a 12-month low of $255.22 and a 12-month high of $374.63.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, July 30th. The medical technology company reported $2.81 EPS for the quarter, topping the consensus estimate of $2.79 by $0.02. Stryker had a return on equity of 22.89% and a net margin of 16.12%. The business had revenue of $5.42 billion for the quarter, compared to analysts’ expectations of $5.40 billion. During the same quarter in the previous year, the firm posted $2.54 earnings per share. The company’s revenue was up 8.5% compared to the same quarter last year. Sell-side analysts expect that Stryker Co. will post 12 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be paid a $0.80 dividend. The ex-dividend date is Monday, September 30th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.88%. Stryker’s dividend payout ratio (DPR) is presently 36.53%.

Insider Activity at Stryker

In other news, insider Viju Menon sold 600 shares of the business’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total value of $213,000.00. Following the completion of the sale, the insider now owns 9,069 shares of the company’s stock, valued at approximately $3,219,495. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Stryker news, insider Viju Menon sold 600 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total transaction of $213,000.00. Following the transaction, the insider now owns 9,069 shares of the company’s stock, valued at $3,219,495. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Glenn S. Boehnlein sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $333.00, for a total value of $6,660,000.00. Following the completion of the sale, the chief financial officer now owns 2,852 shares of the company’s stock, valued at $949,716. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 220,068 shares of company stock valued at $71,811,372 over the last ninety days. Corporate insiders own 5.90% of the company’s stock.

Analyst Upgrades and Downgrades

SYK has been the subject of several recent analyst reports. Needham & Company LLC lifted their price target on Stryker from $392.00 to $393.00 and gave the company a “buy” rating in a report on Thursday, August 1st. UBS Group boosted their target price on shares of Stryker from $351.00 to $366.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Truist Financial increased their price target on shares of Stryker from $345.00 to $370.00 and gave the stock a “hold” rating in a research note on Monday, October 14th. Morgan Stanley lifted their price target on shares of Stryker from $345.00 to $350.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. Finally, Evercore ISI upped their price objective on Stryker from $365.00 to $380.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Four research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $381.16.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.